- Nachrichtendetail
-
08.07.2024 14:05:30 - dpa-AFX: Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it
currently expects that its financial results for the second quarter 2024 will
include an acquired in-process research and development charge of approximately
$24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity
securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net
income per share for the second quarter 2024 by approximately $0.18.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
currently expects that its financial results for the second quarter 2024 will
include an acquired in-process research and development charge of approximately
$24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity
securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net
income per share for the second quarter 2024 by approximately $0.18.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.066,940 | 07.08.24 21:14:18 | +0,750 | +0,07% | 1.065,730 | 1.068,150 | 1.074,380 | 1.066,190 |
